384 related articles for article (PubMed ID: 36694243)
21. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
22. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
23. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
Blanco-Aparicio C; Carnero A
Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
[TBL] [Abstract][Full Text] [Related]
24. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
25. Targeting Pim kinases for cancer treatment: opportunities and challenges.
Le BT; Kumarasiri M; Adams JR; Yu M; Milne R; Sykes MJ; Wang S
Future Med Chem; 2015; 7(1):35-53. PubMed ID: 25582332
[TBL] [Abstract][Full Text] [Related]
26. Pim Kinase Interacts with Nonstructural 5A Protein and Regulates Hepatitis C Virus Entry.
Park C; Min S; Park EM; Lim YS; Kang S; Suzuki T; Shin EC; Hwang SB
J Virol; 2015 Oct; 89(19):10073-86. PubMed ID: 26202252
[TBL] [Abstract][Full Text] [Related]
27. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
[TBL] [Abstract][Full Text] [Related]
28. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
[TBL] [Abstract][Full Text] [Related]
29. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
[TBL] [Abstract][Full Text] [Related]
30. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
31. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
Szydłowski M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Derezińska E; Hoser G; Wasilewska D; Szymańska-Giemza O; Jabłońska E; Białopiotrowicz E; Sewastianik T; Polak A; Czardybon W; Gałęzowski M; Windak R; Zaucha JM; Warzocha K; Brzózka K; Juszczyński P
Blood; 2017 Sep; 130(12):1418-1429. PubMed ID: 28698206
[TBL] [Abstract][Full Text] [Related]
32. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
33. PIM kinases regulate early human Th17 cell differentiation.
Buchacher T; Shetty A; Koskela SA; Smolander J; Kaukonen R; Sousa AGG; Junttila S; Laiho A; Rundquist O; Lönnberg T; Marson A; Rasool O; Elo LL; Lahesmaa R
Cell Rep; 2023 Dec; 42(12):113469. PubMed ID: 38039135
[TBL] [Abstract][Full Text] [Related]
34. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
Xu J; Zhang T; Wang T; You L; Zhao Y
Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
[TBL] [Abstract][Full Text] [Related]
35. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice.
An N; Kraft AS; Kang Y
J Hematol Oncol; 2013 Jan; 6():12. PubMed ID: 23360755
[TBL] [Abstract][Full Text] [Related]
36. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
37. The PIM family of serine/threonine kinases in cancer.
Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
[TBL] [Abstract][Full Text] [Related]
38. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
39. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy.
Panchal NK; Sabina EP
Life Sci; 2020 Aug; 255():117866. PubMed ID: 32479955
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Pim kinases in multiple myeloma.
Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
